Editas Medicine, Inc.

Key Statistics

Recent News

• Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report? Zacks

  Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? Motley Fool

  One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

• Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates Simply Wall St.

  Market forces rained on the parade of Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders today, when the analysts...

• EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus Zacks

  Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.

• Company News for May 6, 2026 Zacks

  Companies in The News Are: MPC,EDIT,BUD,AEP

• Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates Zacks

  Editas (EDIT) delivered earnings and revenue surprises of +11.86% and -67.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

• Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report? Zacks

  Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Zacks

  Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.